| Long-lived intestinal tuft cells serve as colon cancer–initiating cells CB Westphalen, S Asfaha, Y Hayakawa, Y Takemoto, DJ Lukin, AH Nuber, ... The Journal of clinical investigation 124 (3), 1283-1295, 2014 | 398 | 2014 |
| Glutathione synthesis is essential for mouse development but not for cell growth in culture ZZ Shi, J Osei-Frimpong, G Kala, SV Kala, RJ Barrios, GM Habib, ... Proceedings of the National Academy of Sciences 97 (10), 5101-5106, 2000 | 348 | 2000 |
| The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn’s disease: results from the US VICTORY Consortium PS Dulai, S Singh, X Jiang, F Peerani, N Narula, K Chaudrey, ... Official journal of the American College of Gastroenterology| ACG 111 (8 …, 2016 | 312 | 2016 |
| Open: Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ... Official journal of the American College of Gastroenterology| ACG 113 (9), 1345, 2018 | 144 | 2018 |
| Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease PS Dulai, BS Boland, S Singh, K Chaudrey, JL Koliani-Pace, G Kochhar, ... Gastroenterology 155 (3), 687-695. e10, 2018 | 124 | 2018 |
| Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease DJ Lukin, A Kumar, K Hajifathalian, RZ Sharaiha, EJ Scherl, RS Longman, ... Gastroenterology 159 (4), 1541-1544. e2, 2020 | 112 | 2020 |
| Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents J Axelrad, O Bernheim, JF Colombel, S Malerba, A Ananthakrishnan, ... Clinical gastroenterology and hepatology 14 (1), 58-64, 2016 | 102 | 2016 |
| Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis W Ahmed, J Galati, A Kumar, PJ Christos, R Longman, DJ Lukin, E Scherl, ... Clinical Gastroenterology and Hepatology 20 (3), e361-e379, 2022 | 96 | 2022 |
| p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints DJ Lukin, LA Carvajal, W Liu, L Resnick-Silverman, JJ Manfredi Molecular Cancer Research 13 (1), 16-28, 2015 | 86 | 2015 |
| Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases J Meserve, S Aniwan, JL Koliani-Pace, P Shashi, A Weiss, D Faleck, ... Clinical Gastroenterology and Hepatology 17 (8), 1533-1540. e2, 2019 | 84 | 2019 |
| Predictors and management of loss of response to vedolizumab in inflammatory bowel disease E Shmidt, G Kochhar, J Hartke, P Chilukuri, J Meserve, K Chaudrey, ... Inflammatory bowel diseases 24 (11), 2461-2467, 2018 | 63 | 2018 |
| Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis PS Dulai, S Singh, NV Casteele, J Meserve, A Winters, S Chablaney, ... Clinical Gastroenterology and Hepatology 18 (13), 2952-2961. e8, 2020 | 57 | 2020 |
| Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis DM Faleck, A Winters, S Chablaney, P Shashi, J Meserve, A Weiss, ... Clinical Gastroenterology and Hepatology 17 (12), 2497-2505. e1, 2019 | 55 | 2019 |
| p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes PJ Hamard, DJ Lukin, JJ Manfredi Journal of Biological Chemistry 287 (26), 22397-22407, 2012 | 54 | 2012 |
| Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease M Bohm, R Xu, Y Zhang, S Varma, M Fischer, G Kochhar, B Boland, ... Alimentary Pharmacology & Therapeutics 52 (4), 669-681, 2020 | 51 | 2020 |
| Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis D Lukin, D Faleck, R Xu, Y Zhang, A Weiss, S Aniwan, S Kadire, G Tran, ... Clinical Gastroenterology and Hepatology 20 (1), 126-135, 2022 | 41 | 2022 |
| Xenobiotic receptor-mediated regulation of intestinal barrier function and innate immunity HS Ranhotra, KL Flannigan, M Brave, S Mukherjee, DJ Lukin, SA Hirota, ... Nuclear receptor research 3, 2016 | 38 | 2016 |
| A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease PS Dulai, A Amiot, L Peyrin‐Biroulet, V Jairath, M Serrero, J Filippi, ... Alimentary pharmacology & therapeutics 51 (5), 553-564, 2020 | 33 | 2020 |
| OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis M Bohm, SV Sagi, M Fischer, S Kadire, G Tran, M Rahal, S Aniwan, ... Journal of Crohn's and Colitis 12 (supplement_1), S018-S018, 2018 | 28* | 2018 |
| Effect of comorbid conditions on adherence to colorectal cancer screening DJ Lukin, LH Jandorf, RJ Dhulkifl, LD Thélémaque, JA Christie, ... Journal of Cancer Education 27, 269-276, 2012 | 25 | 2012 |
